News & Updates
Showing Dermatology articles
Showing

Bimekizumab safety for moderate to severe plaque psoriasis affirmed
Treatment with bimekizumab for up to 2 years appears to be tolerated well in patients with moderate-to-severe plaque psoriasis, with no increased risk of adverse events (AEs) aside from a higher frequency of mild-to-moderate oral candidiasis, according to pooled analyses of data from eight randomized controlled trials (RCTs).

Adalimumab biosimilar performs well in chronic plaque psoriasis treatment
The adalimumab biosimilar BI 695501 has demonstrated equivalent pharmacokinetics to the reference product, with highly comparable efficacy, immunogenicity, and safety in patients with chronic plaque psoriasis, according to data from the phase III VOLTAIRE-X trial.

Older age, itch, pain predict depression in atopic dermatitis
Depressive symptoms are common among adults with atopic dermatitis (AD) severity and may fluctuate over time, reveals a study. Persistent depression is significantly associated with older age, male sex, severe itch, and skin pain, among others.





